| The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men H Agersø, LB Jensen, B Elbrønd, P Rolan, M Zdravkovic Diabetologia 45, 195-202, 2002 | 644 | 2002 |
| Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans J Soul-Lawton, E Seaber, N On, R Wootton, P Rolan, J Posner Antimicrobial agents and chemotherapy 39 (12), 2759-2764, 1995 | 386 | 1995 |
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects B Elbrønd, G Jakobsen, S Larsen, H Agersø, LB Jensen, P Rolan, J Sturis, ... Diabetes care 25 (8), 1398-1404, 2002 | 378 | 2002 |
| Plasma protein binding displacement interactions--why are they still regarded as clinically important? PE Rolan British journal of clinical pharmacology 37 (2), 125, 1994 | 361 | 1994 |
| Reduction of metformin renal tubular secretion by cimetidine in man. A Somogyi, C Stockley, J Keal, P Rolan, F Bochner British journal of clinical pharmacology 23 (5), 545-551, 1987 | 352 | 1987 |
| Reliability of temporal summation and diffuse noxious inhibitory control S Cathcart, AH Winefield, P Rolan, K Lushington Pain Research and Management 14 (6), 433-438, 2009 | 204 | 2009 |
| Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease P Rolan, MR Hutchinson, KW Johnson Expert opinion on pharmacotherapy 10 (17), 2897-2904, 2009 | 185 | 2009 |
| Cortical hyperexcitability is cortical under-inhibition: evidence from a novel functional test of migraine patients JE Palmer, EP Chronicle, P Rolan, WM Mulleners Cephalalgia 20 (6), 525-532, 2000 | 163 | 2000 |
| Examination of some factors responsible for a food‐induced increase in absorption of atovaquone. PE Rolan, AJ Mercer, BC Weatherley, T Holdich, H Meire, RW Peck, ... British journal of clinical pharmacology 37 (1), 13-20, 1994 | 153 | 1994 |
| Peripheral immune contributions to the maintenance of central glial activation underlying neuropathic pain PM Grace, PE Rolan, MR Hutchinson Brain, behavior, and immunity 25 (7), 1322-1332, 2011 | 142 | 2011 |
| The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men P Rolan, ML Sargentini‐Maier, E Pigeolet, A Stockis British journal of clinical pharmacology 66 (1), 71-75, 2008 | 142 | 2008 |
| Stress and tension-type headache mechanisms S Cathcart, AH Winefield, K Lushington, P Rolan Cephalalgia 30 (10), 1250-1267, 2010 | 139 | 2010 |
| Noxious inhibition of temporal summation is impaired in chronic tension‐type headache S Cathcart, AH Winefield, K Lushington, P Rolan Headache: The Journal of Head and Face Pain 50 (3), 403-412, 2010 | 131 | 2010 |
| The contribution of clinical pharmacology surrogates and models to drug development—a critical appraisal P Rolan British journal of clinical pharmacology 44 (3), 219, 1997 | 127 | 1997 |
| The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males ML Sargentini‐Maier, P Rolan, J Connell, D Tytgat, T Jacobs, E Pigeolet, ... British journal of clinical pharmacology 63 (6), 680-688, 2007 | 120 | 2007 |
| Pharmacokinetics of valsartan in patients with liver disease LJ Brookman, PE Rolan, IS Benjamin, KR Palmer, PJ Wyld, P Lloyd, ... Clinical pharmacology & therapeutics 62 (3), 272-278, 1997 | 119 | 1997 |
| Central mechanisms of stress-induced headache S Cathcart, J Petkov, AH Winefield, K Lushington, P Rolan Cephalalgia 30 (3), 285-295, 2010 | 113 | 2010 |
| Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development P Rolan, AJ Atkinson Jr, LJ Lesko Clinical Pharmacology & Therapeutics 73 (4), 284-291, 2003 | 88 | 2003 |
| Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses P Rolan, JA Gibbons, L He, E Chang, D Jones, MI Gross, JB Davidson, ... British journal of clinical pharmacology 66 (6), 792-801, 2008 | 84 | 2008 |
| Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia R Arya, PE Rolan, R W OOTTON, J Posner, AJ Bellingham British journal of haematology 93 (4), 817-821, 1996 | 84 | 1996 |